ReviewSeminars in oncology2018
Biomarker-driven and molecular targeted therapies for colorectal cancers.
Review in Seminars in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Artificial Intelligence-Guided Analysis of WNT Pathway Alterations: Associations with Genomic Burden and Survival Across African American and Non-Hispanic White Populations, Age Groups, and FOLFOX Treatment in Colorectal Cancer.International journal of molecular sciences · 2026Article
- Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.Genes · 2026Review
- Molecular characteristics of Chinese colorectal cancer patients with microsatellite instability.Translational gastroenterology and hepatology · 2026Article
- Clinical and prognostic characteristics of metastatic colorectal cancer with minorOncology letters · 2025Article
- Cytoplasmic SALL4-A isoform expression as a diagnostic marker of less aggressive tumor behavior in gastric cancer.World journal of surgical oncology · 2025Article
- Article
- Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia.Journal of personalized medicine · 2024Article
- Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite.International journal of medical sciences · 2024Review
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.World journal of gastrointestinal surgery · 2023Review
- Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.BMC cancer · 2021Article
- Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.Molecular cancer research : MCR · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.